Nykredit A S bought a new stake in Cencora, Inc. (NYSE:COR – Free Report) in the 2nd quarter, Holdings Channel.com reports. The fund bought 78,252 shares of the company’s stock, valued at approximately $22,144,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Kemnay Advisory Services Inc. bought a new position in Cencora in the fourth quarter valued at about $25,000. Elyxium Wealth LLC bought a new stake in Cencora during the 4th quarter worth about $27,000. Motiv8 Investments LLC bought a new stake in Cencora during the 4th quarter worth about $29,000. Basepoint Wealth LLC acquired a new position in Cencora during the 4th quarter valued at about $32,000. Finally, Elevation Wealth Partners LLC lifted its position in Cencora by 506.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock valued at $27,000 after purchasing an additional 81 shares during the period. Institutional investors own 97.52% of the company’s stock.
Insider Transactions at Cencora
In other news, Director Lauren M. Tyler bought 550 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average price of $270.23 per share, with a total value of $148,626.50. Following the transaction, the director owned 4,359 shares in the company, valued at $1,177,932.57. This represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. The trade was a 36.74% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.38% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Cencora
Cencora Stock Up 0.1%
Shares of NYSE COR opened at $336.77 on Friday. The stock has a market cap of $64.27 billion, a P/E ratio of 25.02, a P/E/G ratio of 1.91 and a beta of 0.57. The firm has a 50 day moving average price of $311.45 and a 200 day moving average price of $309.74. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54.
Cencora (NYSE:COR – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period last year, the business posted $4.00 earnings per share. Analysts expect that Cencora, Inc. will post 17.87 EPS for the current year.
Cencora declared that its Board of Directors has approved a stock buyback program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.
Cencora Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 14th. Cencora’s dividend payout ratio is currently 17.83%.
Cencora Company Profile
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Stories
- Five stocks we like better than Cencora
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
